Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
298
Recruiting, any sponsor type, condition "melanoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting298
- Completed1,284
298 trials
Showing 1 to 25, recently updated first.
National Cancer Institute (NCI)NIH
NCT05155033 · 78 participants (planned) · Start Aug 18, 2022 · Primary completion Sep 1, 2031
Drug: Pembrolizumab; Aldesleukin · For: Metastatic Melanoma; Advanced Locoregional Melanoma; Metastatic Renal Cell Carcinoma and 1 more
Sites: Bethesda, Maryland
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
John KirkwoodAcademic, hospital or other
NCT07631325 · 28 participants (planned) · Start Nov 30, 2026 · Primary completion Jul 31, 2028
Drug: Axelopran; Nivolumab · For: Unresectable Cutaneous Melanoma
Sites: Pittsburgh, Pennsylvania
National Cancer Institute (NCI)NIH
NCT06066138 · 30 participants (planned) · Start Nov 4, 2025 · Primary completion Jan 31, 2027
Drug: Atezolizumab · For: Locally Advanced Alveolar Soft Part Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Locally Advanced Non Small Cell Lung Cancer and 7 more
Sites: Bethesda, Maryland
John KirkwoodAcademic, hospital or other
NCT07223411 · 20 participants (planned) · Start Nov 19, 2025 · Primary completion Nov 1, 2028
Drug: Fianlimab + Cemiplimab; Relatlimab + Nivolumab · For: Locally Advanced Melanoma
Sites: Pittsburgh, Pennsylvania
- A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Recruiting
Outpace Bio, Inc.Industry
NCT07664735 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2030
Drug: OPB-201 · For: Endometrial Cancer Recurrent; Endometrial Cancer; Advanced Endometrial Cancer and 4 more
Sites: San Francisco, California; Atlanta, Georgia; Detroit, Michigan · 5 sites in all
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT07028008 · 9 participants (planned) · Start Jul 2, 2025 · Primary completion May 28, 2027
Drug: tumor-infiltrating lymphocyte (TIL) · For: Melanoma
Sites: Seoul, South Korea
National Cancer Institute (NCI)NIH
NCT05136196 · 150 participants (planned) · Start Dec 6, 2022 · Primary completion Jan 1, 2027
Drug: Cabozantinib S-malate; Nivolumab · For: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 and 22 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 233 sites in all
St Vincent's Hospital, SydneyAcademic, hospital or other
NCT07203391 · 8 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 1, 2027
Drug: roginolisib · For: Uveal Melanoma, Metastatic
Sites: Sydney, Australia; Melbourne, Australia
Washington University School of MedicineAcademic, hospital or other
NCT05629546 · 33 participants (planned) · Start Nov 6, 2024 · Primary completion Feb 28, 2029
Drug: Cytokine-induced memory-like natural killer cells; Relatilmab and 1 more · For: Advanced Melanoma; Metastatic Melanoma
Sites: St Louis, Missouri
Kupando GmbHIndustry
NCT07600476 · 21 participants (planned) · Start Jul 3, 2026 · Primary completion Dec 2028
Drug: KUP-101A · For: Cutaneous Melanoma; Mucosal Melanoma; Cutaneous Squamous Cell Carcinoma (CSCC) and 2 more
Sites: Munich, Germany; Würzburg, Germany; Marburg, Germany · 4 sites in all
Thomas Jefferson UniversityAcademic, hospital or other
NCT06414590 · 19 participants (planned) · Start Sep 5, 2025 · Primary completion Aug 2027
Drug: Tebentafusp-Tebn · For: Locally Advanced Unresectable Uveal Melanoma
Sites: Philadelphia, Pennsylvania · 2 sites in all
St Vincent's Hospital, SydneyAcademic, hospital or other
NCT07063875 · 8 participants (planned) · Start Jun 1, 2025 · Primary completion Sep 1, 2027
Drug: Aldesleukin · For: Uveal Melanoma; Metastatic Uveal Melanoma; Metastatic Uveal Melanoma in the Liver
Sites: Sydney, Australia; Melbourne, Australia
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on TumorsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07863024 · 320 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 10, 2031
Drug: REGN13089-M404-M2980 · For: Advanced Solid Tumors
Sites: Huntersville, North Carolina
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06172478 · 890 participants (planned) · Start Feb 26, 2024 · Primary completion Nov 19, 2030
Drug: HER3-DXd · For: Advanced Solid Tumor; Melanoma; Head and Neck Cancer and 11 more
Sites: Duarte, California; New Haven, Connecticut; Kissimmee, Florida · 97 sites in all
LG ChemIndustry
NCT06332755 · 76 participants (planned) · Start Jun 5, 2024 · Primary completion Nov 2027
Drug: Phase 1a: LB-LR1109; Phase 1b: LB-LR1109 and Atezolizumab · For: Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC) and 2 more
Sites: Fairfax, Virginia
KaliVir ImmunotherapeuticsIndustry
NCT06444815 · 60 participants (planned) · Start Sep 16, 2024 · Primary completion Sep 30, 2027
Drug: VET3-TGI; Atezolizumab · For: Solid Tumor, Adult; Microsatellite Stable Colorectal Cancer; Head and Neck Squamous Cell Carcinoma and 10 more
Sites: Los Angeles, California; Orange, California; Miami, Florida · 8 sites in all
SystImmune Inc.Industry
NCT07940881 · 400 participants (planned) · Start Aug 24, 2026 · Primary completion Nov 2028
Drug: SI-B037 · For: Locally Advanced /Metastatic Solid Tumors; Locally Advanced / Metastatic Solid Tumors; First in Human and 12 more
Sites: Houston, Texas
NuCana plcAcademic, hospital or other
NCT03829254 · 135 participants (planned) · Start Jun 17, 2019 · Primary completion Jul 2027
Drug: NUC-7738; Pembrolizumab · For: Advanced Cancer; Lymphoma; Solid Tumor and 1 more
Sites: Cambridge, United Kingdom; Edinburgh, United Kingdom; Glasgow, United Kingdom · 9 sites in all
- Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of MelanomaPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT07040280 · 120 participants (planned) · Start Feb 20, 2026 · Primary completion Mar 1, 2031
Drug: Placebo Administration; Sulforaphane · For: Clinical Stage 0 Cutaneous Melanoma AJCC v8; Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8 and 2 more
Sites: Pittsburgh, Pennsylvania
Sun Yat-sen UniversityAcademic, hospital or other
NCT07934927 · 27 participants (planned) · Start Sep 29, 2026 · Primary completion Dec 31, 2029
Drug: Retlirafusp Alfa Injection · For: Melanoma; Immune Checkpoint Inhibitor
Sites: Guangzhou, China
Novelty Nobility, Inc.Industry
NCT06805825 · 67 participants (planned) · Start Feb 3, 2025 · Primary completion Aug 30, 2027
Drug: NN3201 · For: Gastrointestinal Stromal Tumors; Small-cell Lung Cancer; Adenoid Cystic Carcinoma and 4 more
Sites: Ann Arbor, Michigan; Cleveland, Ohio; Portland, Oregon · 5 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02332668 · 370 participants (planned) · Start Mar 19, 2015 · Primary completion Feb 2, 2028
Drug: Pembrolizumab · For: Melanoma; Lymphoma; Solid Tumor and 2 more
Sites: Aurora, Colorado; Chicago, Illinois; Boston, Massachusetts · 15 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.